Non-proliferative Diabetic Retinopathy Treated With Runcaciguat

Completed · Phase 2 · Has a placebo group

Conditions studied: Diabetic Retinopathy

In brief

This Phase 2 study is conducted to investigate the safety and efficacy of runcaciguat in the treatment of diabetic retinopathy. To assess efficacy, the retinal morphology will be investigated by 7-field color fundus photography for central assessment of the diabetic retinopathy severity score, or DRSS. Two-step DRSS improvement at 24 weeks of treatment will be the primary efficacy endpoint. DRSS assessments are repeated after completion of 48 weeks of treatment. In addition, vision threatening complications will be recorded throughout the study and assessed as secondary efficacy endpoint.

Key facts

Study ID
NCT04722991
Run by
Bayer
People needed
109
Starts
2021-03-17
Expected to finish
2024-04-22
Last updated by the study team
2025-04-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.